← Eichor
Study identifier: NCT06274593 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Study of OCT Peripapillary Angiography in Patients With Advanced Glaucoma

Condition: Glaucoma  ·  Sponsor: Nantes University Hospital

PhaseN/A
Planned participants50
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Glaucoma is a chronic disease of the optic nerve, characterized by progressive loss of nerve cells in the retina, leading to progressive loss of peripheral and central vision. There are in fact several types of glaucoma, which is the world's second leading cause of blindness after cataracts, and the leading cause of irreversible blindness. To date, to our knowledge, there is no work analyzing the progression of angiographic OCT in patients with glaucoma. The main aim of this study is to compare the 3-year progression rate of 3 examinations in advanced glaucoma patients: one functional (visual field) and two anatomical (OCTa and OCTrnfl).

This description comes directly from the study's public registry record.

Talk to the study team

Jean-Baptiste Ducloyer, M.D  ·  02 40 08 34 01  ·  jeanbatiste.ducloyer@chu-nantes.fr

Isabelle Orignac, M.D  ·  02 40 08 34 01  ·  isabelle.orignac@chu-nantes.fr

Always discuss trial participation with your own doctor first.

Locations (2)

CHU NantesNantes, Nantes, FranceRecruiting
Jean-Baptiste DucloyerNantes, Nantes, FranceNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06274593